Article Type
Article
Changed
Mon, 11/04/2019 - 14:03

Saad Z. Usmani, MD, FACP, discusses a new treatment option for newly diagnosed, transplant-ineligible patients with multiple myeloma.

Article includes:

  • An important option for patients with multiple myeloma
  • Details on the phase 3 trial
  • Efficacy and safety profile

 

 

 
Sponsor
This supplement is sponsored by Janssen Biotech, Inc.
Publications
MDedge Hematology and Oncology
Topics
Multiple Myeloma
Sections
Supplements
Sponsor
This supplement is sponsored by Janssen Biotech, Inc.
Sponsor
This supplement is sponsored by Janssen Biotech, Inc.

Saad Z. Usmani, MD, FACP, discusses a new treatment option for newly diagnosed, transplant-ineligible patients with multiple myeloma.

Article includes:

  • An important option for patients with multiple myeloma
  • Details on the phase 3 trial
  • Efficacy and safety profile

 

 

 

Saad Z. Usmani, MD, FACP, discusses a new treatment option for newly diagnosed, transplant-ineligible patients with multiple myeloma.

Article includes:

  • An important option for patients with multiple myeloma
  • Details on the phase 3 trial
  • Efficacy and safety profile

 

 

 
Publications
MDedge Hematology and Oncology
Publications
MDedge Hematology and Oncology
Topics
Multiple Myeloma
Article Type
Article
Sections
Supplements
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Tue, 06/18/2019 - 14:30
Un-Gate On Date
Tue, 06/18/2019 - 14:30
Use ProPublica
CFC Schedule Remove Status
Tue, 06/18/2019 - 14:30
Hide sidebar & use full width
render the right sidebar.
Teaser Media